Ambalal Sarabhai Enterprises Ltd
Incorporated in 1977, Ambalal Sarabhai Enterprises Ltd is in the business of manufacturing Pharmaceuticals and Electronics[1]
- Market Cap ₹ 242 Cr.
- Current Price ₹ 31.6
- High / Low ₹ 68.0 / 30.0
- Stock P/E 25.7
- Book Value ₹ 7.17
- Dividend Yield 0.00 %
- ROCE 6.01 %
- ROE 6.80 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 4.40 times its book value
- Promoter holding is low: 31.4%
- Tax rate seems low
- Company has a low return on equity of 8.72% over last 3 years.
- Earnings include an other income of Rs.17.1 Cr.
- Working capital days have increased from -538 days to 109 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.67 | 15.25 | 6.98 | 1.51 | 0.92 | 0.00 | 0.00 | 0.00 | 0.13 | 3.71 | 3.81 | 4.04 | 5.33 | |
| 29.02 | 27.30 | 28.62 | 14.47 | 21.76 | 8.86 | 7.86 | 11.69 | 5.71 | 8.87 | 8.61 | 11.37 | 12.43 | |
| Operating Profit | -13.35 | -12.05 | -21.64 | -12.96 | -20.84 | -8.86 | -7.86 | -11.69 | -5.58 | -5.16 | -4.80 | -7.33 | -7.10 |
| OPM % | -85.19% | -79.02% | -310.03% | -858.28% | -2,265.22% | -4,292.31% | -139.08% | -125.98% | -181.44% | -133.21% | |||
| 3.43 | 14.17 | 95.94 | -0.63 | 24.49 | 6.46 | 24.61 | 3.16 | 9.47 | 9.75 | 7.89 | 15.85 | 17.13 | |
| Interest | 9.12 | 7.91 | 1.99 | 2.62 | 1.05 | 0.62 | 0.46 | 0.56 | 0.25 | 0.11 | 2.16 | 0.34 | 0.30 |
| Depreciation | 1.52 | 3.36 | 14.62 | 2.45 | 0.42 | 0.40 | 0.39 | 0.38 | 0.19 | 0.15 | 0.12 | 0.10 | 0.08 |
| Profit before tax | -20.56 | -9.15 | 57.69 | -18.66 | 2.18 | -3.42 | 15.90 | -9.47 | 3.45 | 4.33 | 0.81 | 8.08 | 9.65 |
| Tax % | 0.00% | 0.00% | 20.80% | 10.18% | 166.06% | 13.45% | 2.20% | -0.84% | 14.49% | 5.31% | -217.28% | -1.98% | |
| -20.57 | -9.15 | 45.68 | -20.57 | -1.44 | -3.88 | 15.55 | -9.39 | 2.96 | 4.11 | 2.58 | 8.24 | 9.97 | |
| EPS in Rs | -2.68 | -1.19 | 5.96 | -2.68 | -0.19 | -0.51 | 2.03 | -1.23 | 0.39 | 0.54 | 0.34 | 1.08 | 1.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | % |
| 3 Years: | 214% |
| TTM: | 117% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -28% |
| 3 Years: | -4% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 6% |
| 3 Years: | 4% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | 6% |
| 3 Years: | 9% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 | 76.63 |
| Reserves | -64.34 | -73.49 | -27.80 | -46.41 | -47.98 | -51.85 | -36.39 | -45.85 | -42.93 | -38.79 | -36.34 | -28.14 | -21.66 |
| 27.27 | 30.10 | 29.54 | 22.13 | 11.07 | 11.07 | 11.00 | 11.14 | 9.77 | 11.49 | 10.03 | 7.66 | 8.76 | |
| 97.45 | 103.24 | 65.13 | 63.81 | 91.28 | 102.78 | 73.35 | 58.14 | 39.53 | 30.42 | 30.96 | 26.77 | 19.14 | |
| Total Liabilities | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.75 | 81.28 | 82.92 | 82.87 |
| 46.41 | 42.66 | 20.60 | 16.43 | 14.98 | 14.65 | 14.48 | 13.97 | 13.00 | 12.86 | 12.84 | 12.22 | 12.18 | |
| CWIP | 0.10 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 56.16 | 56.29 | 82.91 | 76.19 | 55.88 | 55.97 | 56.43 | 26.58 | 25.54 | 25.54 | 25.39 | 25.34 | 25.34 |
| 34.34 | 37.43 | 39.99 | 23.54 | 60.14 | 68.01 | 53.68 | 59.51 | 44.46 | 41.35 | 43.05 | 45.36 | 45.35 | |
| Total Assets | 137.01 | 136.48 | 143.50 | 116.16 | 131.00 | 138.63 | 124.59 | 100.06 | 83.00 | 79.75 | 81.28 | 82.92 | 82.87 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.43 | -12.05 | -69.37 | -3.67 | -12.66 | -3.27 | -4.53 | -10.42 | -7.79 | 1.52 | -3.82 | -4.08 | |
| 2.34 | 12.70 | 75.22 | 8.64 | 26.14 | 2.37 | 4.92 | 15.76 | 20.77 | 0.61 | 3.48 | 6.35 | |
| -4.00 | -0.75 | -2.56 | -8.14 | -12.15 | -0.44 | -0.42 | -0.32 | -16.46 | -3.76 | 0.30 | -2.31 | |
| Net Cash Flow | -0.23 | -0.10 | 3.30 | -3.17 | 1.33 | -1.33 | -0.03 | 5.02 | -3.47 | -1.63 | -0.04 | -0.04 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 78.26 | 37.34 | 1.57 | 0.00 | 0.00 | 421.15 | 29.51 | 37.36 | 37.04 | |||
| Inventory Days | 5.63 | 76.36 | 22.52 | 47.93 | 56.64 | 0.00 | 2.01 | 0.00 | 0.00 | |||
| Days Payable | 391.01 | 320.68 | 729.22 | 3,974.44 | 13,253.28 | 1,611.83 | ||||||
| Cash Conversion Cycle | -307.12 | -206.97 | -705.13 | -3,926.52 | -13,196.64 | 421.15 | -1,580.31 | 37.36 | 37.04 | |||
| Working Capital Days | -2,072.60 | -2,355.15 | -3,035.57 | -16,105.93 | -23,784.51 | -30,660.00 | -1,037.94 | -686.89 | 109.32 | |||
| ROCE % | -22.31% | -34.09% | -59.62% | -12.82% | -21.98% | -7.41% | 36.90% | -4.27% | 9.93% | 11.12% | 5.96% | 6.01% |
Documents
Announcements
-
Results For The Quarter And Half Year Ended 30.09.2025
17h - Approved unaudited consolidated and standalone Q2/H1 results to Sept 30, 2025; consolidated H1 PAT Rs 766.32 lakhs
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 12.11.2025
17h - Board approved Q2/H1 results (30 Sep 2025): H1 consolidated profit Rs766.32 lakh; Q2 loss Rs56.03 lakh.
-
Announcement Under Regulation 30 Of SEBI (LODR)
6 Nov - Co-Diagnostics engaged Maxim on Nov 5, 2025 to pursue SPAC listing for CoSara Diagnostics (Ambalal Sarabhai JV).
-
Board Meeting Intimation for Approval Of Unaudited Financial Results Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended September 30, 2025 Along With Limited Review Report Of Auditors Thereon.
4 Nov - Board meeting Nov 12, 2025 to approve Q2/H1 results for Sept 30, 2025; trading window Oct1–Nov14.
-
Announcement Under Regulation 30 Of SEBI (LODR)
27 Oct - Telerad (Systronics division) won Best Regional Distributor — Broadcast West at Broadcast India Show 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ASE is a pharmaceutical health care companies, which through its group companies, manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and abroad